New drug combo before transplant aims to beat rare lymphoma
NCT ID NCT07276737
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three chemotherapy drugs (thiotepa, cyclophosphamide, and busulfan) given before a stem cell transplant for people with NK/T-cell lymphoma. The goal is to see if this approach helps keep the cancer from coming back. About 37 adults aged 18-70 who have achieved remission will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK CELL LYMPHOMA/LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for tough lymphoma: TR115 faces off against standard care
- New blood test could help monitor T-Cell lymphoma
- New vaccine aims to fight Hard-to-Treat EBV cancers
- New combo attack on rare blood cancer shows promise in early trial
- Triple-Drug attack aims to beat rare lymphoma
- New combo therapy aims to cut relapse in rare lymphoma